S. KILIÇKAP Et Al. , "The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey," ESMO (European Society for Medical Oncology) 2018 Congress , vol.29, Munich, Germany, 2018
KILIÇKAP, S. Et Al. 2018. The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey. ESMO (European Society for Medical Oncology) 2018 Congress , (Munich, Germany).
KILIÇKAP, S., ÖLMEZ, Ö. F., ÇİÇİN, İ., DEMİRCİ, U., ALAN, Ö., ÇABUK, D., ... ŞAKALAR, T.(2018). The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey . ESMO (European Society for Medical Oncology) 2018 Congress, Munich, Germany
KILIÇKAP, SAADETTİN Et Al. "The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey," ESMO (European Society for Medical Oncology) 2018 Congress, Munich, Germany, 2018
KILIÇKAP, SAADETTİN Et Al. "The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey." ESMO (European Society for Medical Oncology) 2018 Congress , Munich, Germany, 2018
KILIÇKAP, S. Et Al. (2018) . "The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey." ESMO (European Society for Medical Oncology) 2018 Congress , Munich, Germany.
@conferencepaper{conferencepaper, author={SAADETTİN KILIÇKAP Et Al. }, title={The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey}, congress name={ESMO (European Society for Medical Oncology) 2018 Congress}, city={Munich}, country={Germany}, year={2018}}